National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 68506-68507 [2022-24731]
Download as PDF
<![CDATA[
68506
Federal Register / Vol. 87, No. 219 / Tuesday, November 15, 2022 / Notices
attend and need special assistance or
another reasonable accommodation
should notify ACBSCT at the address
and phone number listed above at least
10 business days prior to the meeting.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2022–24788 Filed 11–14–22; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notice for Public Comments on
Healthcare-Associated Infections (HAI)
National Action Plan Targets
Office of Infectious Disease and
HIV/AIDS Policy, Office of the Assistant
Secretary for Health, Department of
Health and Human Services, Office of
the Secretary, Department of Health and
Human Services.
ACTION: Notice for public comment.
AGENCY:
The Department of Health and
Human Services’ (HHS) Office of
Infectious Disease and HIV/AIDS Policy
(OIDP) in the Office of the Assistant
Secretary for Health (OASH) announces
the draft targets for updating the
Healthcare-Associated Infections (HAI)
National Action Plan, Phase 1, Acute
Care Hospitals, for public comment. The
HHS Core Group of the HAI National
Action Plan reviewed data prepandemic and between 2020 and 2021
and developed potential 5-year targets
based on assumptions that current HAI
rates should return to pre-pandemic
baseline rates within 2 years or within
3 years when determining these 5-year
targets. The HHS HAI NAP Core Group
recommends 5-year targets assuming a
return to pre-pandemic baseline rates
within 3 years based on two
fundamentals: (1) pandemic-related
challenges will likely persist in
upcoming years, and (2) the pandemic
has caused major strains on the health
care system which make a 3-year
timeline to achieve pre-pandemic
Standardized Infection Ratio (SIR) the
most appropriate choice. The draft
targets are below.
DATES: All comments must be received
by 5:00 p.m. ET on January 13, 2023, to
be considered.
ADDRESSES: All comments must be
submitted electronically to OIDP-HAI@
hhs.gov to be considered.
FOR FURTHER INFORMATION CONTACT:
Chinedu R. Okeke, OIDP, Medical
Officer at chinedu.okeke@hhs.gov or
202–868–8872.
SUPPLEMENTARY INFORMATION: Healthcare
Associated Infections (HAIs) are
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
19:16 Nov 14, 2022
Jkt 259001
infections that patients get while
receiving care or treatment, and many
HAIs are preventable. Modern
healthcare employs many types of
invasive devices and procedures to treat
patients and to help them recover.
Infections can be associated with
surgeries and the devices used in
medical procedures, such as catheters or
ventilators and due to the transmission
of pathogens. HAIs are an important
cause of morbidity and mortality in the
United States and are associated with a
substantial increase in healthcare costs
each year. At any given time in the US,
1 out of every 31 hospitalized patients
are affected by an HAI. HAIs occur in
all types of care settings, including
acute care hospitals, ambulatory
surgical centers, dialysis facilities,
outpatient care, and long-term care
facilities. The updates here are for phase
1 of the action plan, which focuses on
acute care hospitals.
HAIs are a significant source of
complications across the continuum of
care and can be transmitted between
different healthcare facilities. However,
recent studies suggest that
implementing existing prevention
practices can lead up to a 70 percent
reduction in certain HAIs. Likewise,
recent modeling data suggests that
substantial reductions in resistant
bacteria, like MRSA, can be achieved
through coordinated activities between
healthcare facilities in each region. The
financial benefit of using these
prevention practices is estimated to be
$25 billion to $31.5 billion in medical
cost savings. Risk factors for HAIs can
be grouped into three general categories:
medical procedures and antibiotic use,
organizational factors, including risks
for pathogen transmission, and patient
characteristics. The behaviors of health
care providers and their interactions
with the health care system also
influence the rate of HAIs.
To provide a roadmap for HAI
prevention, HHS released the National
Action Plan to Prevent Health CareAssociated Infections: Roadmap to
Elimination (HAI National Action Plan)
in 2009 with updates to phase 1, acute
care hospitals made in 2013 and 2018.
In 2020, HHS leadership transitioned
the HAI portfolio to the Office of
Infectious Disease and HIV/AIDS Policy
(OIDP). To date, OIDP is the lead for the
federal steering committee and charged
with leading the process to update the
HAI National Action Plan. Due to the
COVID–19 pandemic, HHS and
implementing agencies delayed the
process of updating the national action
plan and indicator targets for HAIs in
acute care hospitals due to data
instability. This proposed update would
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
include new indicator targets for certain
HAIs in acute care hospitals.
Goals
All Goals Are Five-Year Goals With the
Baseline Year Being 2023 and the Goal
Year Being 2028
• Reduce central line-associated
bloodstream infections (CLABSI) in
intensive care units and ward-located
patients by 40% from 2023–2028
• Reduce catheter-associated urinary
tracts infections (CAUTI) in intensive
care units and ward-located patients
by 25% from 2023–2028
• Reduce hospital-onset MRSA
bacteremia by 40% from 2023–2028
• Reduce hospital-onset Clostridioides
difficile infections (CDI) by 20% from
2023–2028
Of note, the previous iteration of the
HAI national action plan included
targets for reducing surgical site
infections (SSI). However, during the
period of 2020–2022, there has been
significant data instability for SSI due to
variable surgical volume related to
deferral of elective surgeries in hospitals
undergoing COVID surges. The HAI
national action plan Core Group
therefore decided not to establish targets
for SSI at this time.
Information Needs
HHS seeks to obtain feedback from
external stakeholders on the following:
1. Are the draft targets realistic and
achievable?
2. Are there any critical gaps in the
draft targets? If so, please specify the
gaps.
3. Do you have any concerns about
the targets? If so, please specify, and
describe the concern regarding it.
Each commenter is limited to a
maximum of seven pages.
Dated: November 2, 2022,
B. Kaye Hayes,
Deputy Assistant Secretary for Infectious
Disease, Director, Office of Infectious Disease
and HIV/AIDS Policy, Executive Director,
Presidential Advisory Council on HIV/AIDS,
Office of the Assistant Secretary for Health,
Department of Health and Human Services.
[FR Doc. 2022–24822 Filed 11–14–22; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\15NON1.SGM
15NON1
Federal Register / Vol. 87, No. 219 / Tuesday, November 15, 2022 / Notices
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR22–069 High
Impact, Interdisciplinary Science in NIDDK
Research Areas: Adipocyte Heterogeneity
(RC2).
Date: December 6, 2022.
Time: 11:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of Diabetes and Digestive
and Kidney Diseases, 2 Democracy, 6707
Democracy Blvd., Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ann A Jerkins, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7119, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, 301–594–2242,
jerkinsa@niddk.nih.gov.
Information is also available on the
Institute’s/Center’s home page:
www.niddk.nih.gov/, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: November 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–24731 Filed 11–14–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
VerDate Sep<11>2014
19:16 Nov 14, 2022
Jkt 259001
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Cooperative Agreement (U01
Clinical Trial Required).
Date: December 9, 2022.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G54,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Hitendra S. Chand, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G54, Rockville, MD
20852, (240) 627–3245, hiten.chand@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 8, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–24774 Filed 11–14–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Emerging
Imaging Technologies and Applications.
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
68507
Date: December 6, 2022.
Time: 9:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lawrence Edward
Kagemann, Ph.D., Scientific Review Officer,
Center for Scientific Review, 6701 Rockledge
Drive, Bethesda, MD 20892, (301) 480–6849,
larry.kagemann@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–24729 Filed 11–14–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NINDS Special Emphasis
Panel.
Date: December 5–6, 2022.
Time: 10:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Marilyn Moore-Hoon,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Activities, NINDS/NIH, NSC, 6001 Executive
Boulevard, Bethesda, MD 20892, 301–827–
9087, mooremar@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
E:\FR\FM\15NON1.SGM
15NON1
]]>Agencies
[Federal Register Volume 87, Number 219 (Tuesday, November 15, 2022)]
[Notices]
[Pages 68506-68507]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-24731]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
[[Page 68507]]
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; PAR22-069 High Impact,
Interdisciplinary Science in NIDDK Research Areas: Adipocyte
Heterogeneity (RC2).
Date: December 6, 2022.
Time: 11:30 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases, 2 Democracy, 6707
Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ann A Jerkins, Ph.D., Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 7119,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, 301-594-2242,
[email protected].
Information is also available on the Institute's/Center's home
page: www.niddk.nih.gov/, where an agenda and any additional
information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: November 8, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-24731 Filed 11-14-22; 8:45 am]
BILLING CODE 4140-01-P
